ArticleBritish journal of cancer2008
Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.Antibodies (Basel, Switzerland) · 2025Article
- An Overview of Target Membrane Proteins for Near-Infrared Photoimmunotherapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Adjuvant properties of IFN-γ and GM-CSF in the scFv6.C4 DNA vaccine against CEA-expressing tumors.Gene therapy · 2023Article
- CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens.Genes & cancer · 2023Review
- Immunotherapeutic progress and application of bispecific antibody in cancer.Frontiers in immunology · 2022Review
- Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds.Journal of biological engineering · 2021Article
- A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer.Molecular medicine reports · 2017Article
- Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen.Cancer medicine · 2017Article
- Targeted nanoparticles for colorectal cancer.Nanomedicine (London, England) · 2016Review
- Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.British journal of cancer · 2013Article
- Potential targets for pancreatic cancer immunotherapeutics.Immunotherapy · 2011Review
- Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.British journal of cancer · 2009Article
- Monoclonal antibodies in the treatment of pancreatic cancer.Immunotherapy · 2009Review
- In vitro and in vivo anticancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies.British journal of cancer · 2008Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The distribution of carcinoembryonic antigen (CEA) in colorectal cancer (CRC) differs from that in normal colorectal tissue, being found on all borders of the cell membrane and hence enabling access to intravenous antibody, making CEA a good target for antibody-based therapy. The distinctive anti-CEA antibody, PR1A3, binds only membrane-bound CEA. Humanised PR1A3 (hPR1A3) was assessed both in vitro cytotoxicity and binding assays with colorectal cancer cell lines expressing varying levels of CEA. Human peripheral blood mononuclear cells (PBMCs) and purified natural killer (NK) cells were used as effectors. The in vitro assays demonstrated hPR1A3 CEA-specific binding and antibody-dependent and CEA-specific killing of human colorectal cancer cell lines by human PBMCs. The effect increased with increasing concentration of antibody and surface CEA, and was lost by using the parent murine IgG1 PR1A3. Killing was also blocked by antibody to the Fc-gammaIIIA receptor. Purified human NK cells were effective at much lower effector:target ratios than unfractionated PBMCs, indicating that NK cells were the main mediators of hPR1A3-based CEA-specific killing. The results support the development of hPR1A3 for therapy of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.